-
公开(公告)号:US09783527B2
公开(公告)日:2017-10-10
申请号:US14854433
申请日:2015-09-15
申请人: AbbVie Inc.
发明人: Jerome F. Daanen , David A. DeGoey , Jennifer M. Frost , John R. Koenig , Steve Latshaw , Mark Matulenko , Marc Scanio , Lei Shi , William H. Bunnelle
IPC分类号: A61K31/497 , A61K31/4178 , A61K31/4985 , C07D403/04 , C07D403/14 , C07D487/14 , C07D491/08 , C07D413/14 , C07D405/14 , C07D417/14 , C07D401/14
CPC分类号: C07D403/14 , A61K31/4178 , A61K31/497 , A61K31/4985 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/14 , C07D491/08
摘要: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号:US20160075692A1
公开(公告)日:2016-03-17
申请号:US14854433
申请日:2015-09-15
申请人: AbbVie Inc.
发明人: Jerome F. Daanen , David A. DeGoey , Jennifer M. Frost , John R. Koenig , Steve Latshaw , Mark Matulenko , Marc Scanio , Lei Shi , William H. Bunnelle
IPC分类号: C07D403/14 , C07D401/14 , C07D405/14 , C07D491/08 , C07D413/14 , C07D403/04 , C07D417/14
CPC分类号: C07D403/14 , A61K31/4178 , A61K31/497 , A61K31/4985 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/14 , C07D491/08
摘要: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
摘要翻译: 式(I)化合物及其药学上可接受的盐,酯,酰胺或放射性标记形式,其中A,R 1和R 2如说明书中所定义,可用于治疗由电压门控钠通道预防或改善的病症或障碍 ,例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式(I)化合物的药物组合物,以及使用这些化合物和组合物的方法。
-
公开(公告)号:US09156788B2
公开(公告)日:2015-10-13
申请号:US13761862
申请日:2013-02-07
申请人: AbbVie Inc.
发明人: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Eric A. Voight
IPC分类号: A61K31/444 , C07D213/30 , C07D239/26 , C07D401/04 , C07D405/12 , C07D213/50 , C07D401/12
CPC分类号: C07D213/30 , C07D213/50 , C07D239/26 , C07D401/12 , C07D405/12
摘要: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
摘要翻译: 本文公开了式(I)的TRPV3的调节剂,其中G1,X1,X2,X3,X4,X5,G2,Z1,Ra,Rb,u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US08859584B2
公开(公告)日:2014-10-14
申请号:US13716837
申请日:2012-12-17
申请人: AbbVie Inc.
发明人: Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC分类号: A61K31/44 , A61K31/35 , A61K31/47 , A61K31/17 , C07D215/46 , C07D498/02 , C07D311/68 , A61K45/06 , C07D311/96 , C07D311/04 , C07C275/30 , A61K31/192 , C07D311/70 , A61K31/353 , C07D491/052 , A61K31/436 , C07D215/42 , C07C275/32
CPC分类号: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
摘要: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
摘要翻译: 本文公开了式(I)化合物或其药学上可接受的盐,其中X1,L,Rx,Ry,Rz,A,m,n,p,q,s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号:US20130150409A1
公开(公告)日:2013-06-13
申请号:US13761862
申请日:2013-02-07
申请人: AbbVie Inc.
发明人: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Eric A. Voight
IPC分类号: A61K31/44 , C07D401/04 , A61K31/444
CPC分类号: C07D213/30 , C07D213/50 , C07D239/26 , C07D401/12 , C07D405/12
摘要: Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
摘要翻译: 本文公开了式(I)的TRPV3的调节剂,其中G1,X1,X2,X3,X4,X5,G2,Z1,Ra,Rb,u和p如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US08772500B2
公开(公告)日:2014-07-08
申请号:US13658374
申请日:2012-10-23
申请人: AbbVie Inc.
发明人: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt
IPC分类号: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC分类号: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
摘要: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
摘要翻译: 本文公开了式(II)的TRPV3的调节剂:其中G1,X1,X2,X3,X4,X5,G2,Ra,Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US08772499B2
公开(公告)日:2014-07-08
申请号:US13658355
申请日:2012-10-23
申请人: AbbVie Inc.
发明人: Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC分类号: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC分类号: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
摘要: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
摘要翻译: 本文公开了式(I)的TRPV3的调节剂,其中p为1,2,3或4,并且G1,X1,X2,X3,X4,X5,G2,Z1,Ra,Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号:US20130172334A1
公开(公告)日:2013-07-04
申请号:US13716862
申请日:2012-12-17
申请人: AbbVie Inc.
发明人: Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC分类号: C07D405/12 , A61K31/192 , C07D239/80 , C07D413/12 , A61K31/4704 , C07D491/052 , A61K31/517 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/38
CPC分类号: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
摘要: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
摘要翻译: 本文公开了式(I)的化合物或其药学上可接受的盐,其中X1,L,Rx,Ry,G,Z,A,m,n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号:US20130158067A1
公开(公告)日:2013-06-20
申请号:US13716837
申请日:2012-12-17
申请人: AbbVie Inc.
发明人: Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC分类号: C07D311/04 , A61K45/06 , A61K31/192 , C07D311/96 , A61K31/436 , A61K31/47 , C07C275/30 , A61K31/17 , C07C275/32 , C07D491/052 , A61K31/353 , C07D215/46
CPC分类号: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
摘要: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
摘要翻译: 本文公开了式(I)化合物或其药学上可接受的盐,其中X1,L,Rx,Ry,Rz,A,m,n,p,q,s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号:US08969325B2
公开(公告)日:2015-03-03
申请号:US13716862
申请日:2012-12-17
申请人: AbbVie Inc.
发明人: Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC分类号: C07D405/12 , C07D215/38 , C07D239/80 , C07D413/12 , C07D491/052 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D413/14 , C07D215/227 , C07D265/36
CPC分类号: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
摘要: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
摘要翻译: 本文公开了式(I)的化合物或其药学上可接受的盐,其中X1,L,Rx,Ry,G,Z,A,m,n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
-
-
-
-
-
-
-
-